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Data on extrahepatic cancers (EHCs) in compensated viral cirrhosis are limited. The
objective of the prospective multicenter Agence Nationale de Recherche sur le SIDA
et les Hépatites virales CO12 CirVir cohort was to assess the occurrence of all clinical
events in patients with compensated viral cirrhosis, including all types of cancer.
Patients with the following inclusion criteria were enrolled in 35 French centers: (1)
biopsy-proven hepatitis B virus (HBV) or hepatitis C virus (HCV) cirrhosis, (2) Child-
Pugh A, or (3) absence of previous liver complications including primary liver cancer
(PLC). Patients were followed up prospectively every 6 months. The standardized
mortality ratio (SMR) was calculated according to age and gender using 5-year
periods. The impact of sustained viral response (SVR) in HCV patients and
maintained viral suppression in HBV patients were assessed using time-dependent
analysis. A total of 1,671 patients were enrolled between 2006 and 2012 (median age,
54.9 years; men, 67.3%; HCV, 1,323; HBV, 317; HCV-HBV, 31). Metabolic features
and excessive alcohol and tobacco consumption were recorded in 15.2%, 36.4%, and
56.4% of cases, respectively. After a median follow-up of 59.7 months, 227 PLCs were
diagnosed (5-year cumulative incidence [CumI] 13.4%) and 93 patients developed
EHC (14 patients with lymphoid or related tissue cancer and 79 with solid tissue
cancer; 5-year EHC CumI, 5.9%). Compared to the general French population,
patients were younger at cancer diagnosis, with significantly higher risk of EHC in
HCV patients (SMR, 1.31; 95 confidence interval [CI], 1.04-1.64; P = 0.017) and after
SVR (SMR = 1.57; 95% CI, 1.08-2.22; P = 0.013). EHC was the fourth leading cause
of death in the whole cohort and the first in patients with viral control/eradication.
CONCLUSION: Compared to the general French population, HCV cirrhosis is
associated with a higher risk of EHC and the first cause of death in patients with viral























































Publié sur Okina (http://okina.univ-angers.fr)
